In vitro variables of buffy coat–derived platelet concentrates with residual plasma of down to 10% are stably maintained in new‐generation platelet additive solutions

Publisher： John Wiley & Sons Inc

E-ISSN： 1537-2995|55|7|1700-1709

ISSN： 0041-1132

Source： TRANSFUSION, Vol.55, Iss.7, 2015-07, pp. : 1700-1709

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Metabolomic analysis of platelets during storage: a comparison between apheresis‐ and buffy coat–derived platelet concentrates

By  

TRANSFUSION, Vol. 55, Iss. 2, 2015-02 ,pp. : 301-313

John Wiley & Sons Inc

Access to resources Recommend Favorite

Determining the Volume of Additive Solution and Residual Plasma in Whole Blood Filtered and Buffy Coat Processed Red Cell Concentrates

By  

Transfusion Medicine and Hemotherapy, Vol. 43, Iss. 2, 2015-11 ,pp. : 133-136

Karger

Access to resources Recommend Favorite

Pathogen inactivation of double‐dose buffy‐coat platelet concentrates photochemically treated with amotosalen and UVA light: preservation of in vitro function

By  

VOX SANGUINIS, Vol. 108, Iss. 4, 2015-05 ,pp. : 340-349

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of Buffy Coat Platelets in Platelet Additive Solution with the Mirasol® Pathogen Reduction Technology System

By  

Transfusion Medicine and Hemotherapy, Vol. 40, Iss. 1, 2013-01 ,pp. : 44-48

Karger

Access to resources Recommend Favorite

In vitro Properties of Platelet Concentrates

By  

Transfusion Medicine and Hemotherapy, Vol. 28, Iss. 1, 2001-02 ,pp. : 9-14

Karger

Access to resources Recommend Favorite